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IL-12 is a cytokine with links to both innate and adaptive immunity systems. Inmice, its deletion leads to acute susceptibility to oral
infection with the yeast Candida albicans, whereas suchmice are resistant to systemic disease. However, it is an essential component
of the adaptive response that leads to the generation of Th1-type cytokine responses and protection against disseminated disease.
This paper presents an overview of the role of IL-12 in models of systemic and mucosal infection and the possible relationships
between them.
1. Introduction
Candida albicans is a ubiquitous commensal yeast in the
human oral cavity and gastrointestinal tract, as well as
in the genital area of otherwise healthy females. While
many individuals are asymptomatic, carriage increases the
risks of contracting systemic infections [1, 2]. Virtually all
clinical manifestations of disease tend to be associated with
deficiency or dysfunction of the innate or adaptive arms of
the immune system. Patients with defects in cell-mediated
immunity tend to be susceptible to mucocutaneous, but not
to disseminated, candidiasis, whereas systemic infections are
more commonly associated with neutropenia or dysregula-
tion of neutrophil function.
Candidiasis manifests as a symptom of a number of
clinical conditions that have been extensively discussed
elsewhere [3]. Our understanding of host responses to
this pathogen remains incomplete; however, emerging data,
depicted in Figure 1, indicate that the production of key
cytokines, such as IL-12 and IL-23, by the innate immune
system is essential in the recruitment of appropriate adaptive
responses in mucocutaneous disease.
2. The IL-12 Family: Structure and Function
IL-12 is a cytokine produced predominantly by innate
immune cells, including epithelial cells, dendritic cells, and
macrophages, although it is often referred to as a B cell
cytokine. It acts as a multimer linked by disulphide bonds—
most commonly as the p70 heterodimer consisting of p35
and p40 subunits, although the p40 homodimer, sometimes
referred to as IL-12p80, is the dominant eﬀector molecule
produced by epithelial cells. All forms of IL-12 bind to the
IL-12 receptor, which is also a heterodimer of IL-12Rb1 and
RbII subunits that are expressed predominantly on T cells
and on natural killer (NK) cells. IL-12 plays a critical role
in inducing Th1 responses [4], which in turn leads to the
production of a number of cytotoxic cytokines, as well as
interferon-gamma (IFN-γ) by T cells. IFN-γ is itself a major
determinant of Th1 maturation and a dominant modifier of
phagocyte phenotypes.
The p40 subunit of IL-12 is shared with IL-23, a related
cytokine with profound diﬀerences in the cellular outcomes
that it elicits. IL-23 is a heterodimer of IL-12p40 and
IL-23p19 [5] and is also expressed by innate immune cells in
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Figure 1: A schematic illustrating known and postulated pathways of response to infection with Candida albicans. Interaction with epithelial
cells causes the release of cytokines and chemokines that recruit and activate inflammatory and immune cells, including phagocytes, antigen
presenting cells (APCs), and T cells. Phagocytic cells engulf the invading fungus and kill via the respiratory burst and cytokine release,
whereas APCs process the Candida antigens and migrate to the lymph nodes to present them, in the context of the MHC Class II molecule,
to naive CD4 T cells, which are then activated and diﬀerentiate to either a Th1-type or a Th17-type cell. The dominant outcome (Th1
or Th17) is probably determined by the prevailing cytokine milieu. On reaching the infected site, Th1 eﬀector cells release cytokines that
orchestrate containment of infection to the mucosal surfaces and prevent dissemination. Th17 cells release IL-17, thereby enhancing the
candidacidal activity of neutrophils. Thus, both innate and adaptive components of the immune system work cooperatively to provide an
eﬀective defence against the invading yeast.
response to Candida challenge. The IL-23 receptor complex
also shares a subunit with the IL-12R, binding with high
aﬃnity to the IL-12Rb1 subunit but in a heterodimer with a
novel IL-23R subunit. The ability of human T cells or mouse
bone-marrow derived macrophages to respond to IL-12 or
IL-23 is dependent on diﬀerential expression of the IL-12Rb2
or IL-23R subunits, respectively [6].
IL-23 and IL-12 appear to have important and com-
plementary roles in the induction of T-cell responses to
Candida. Most significantly, IL-23 is essential for polarisation
of the Th17 response [7], which has an increasingly impor-
tant role in the host response to Candida infection [8]. It
also increases local activity of the matrix metalloproteinase,
MMP-9, increases angiogenesis, and reduces CD8+ T-cell
infiltration [9].
Because of the structural similarities and shared receptor
subunits, mouse knockout studies describing the eﬀects
of IL-12 may in fact be reporting compound phenotypes.
In particular, IL-12p40-null animals will be null for three
molecules: IL-12p70, IL-12p80, and IL-23. The role of
IL-12p80, which is capable of binding both the IL-12R and
IL-23R via the IL-12Rb1 subunit, also generates a phenotype
that remains underexplored in mouse models of candidiasis,
or in human clinical disease, because of this structural
overlap.
3. Dissecting the Role of
IL-12/IL-23 in Candidiasis Using
Experimental Mouse Models
C. albicans appears to be unique in its ability to infect
a variety of tissues and organs, including kidney, brain,
oral and vaginal mucosa, skin, and gastrointestinal tract.
This has led to the establishment of a plethora of animal
models [10], many with quite disparate objectives, and
although each oﬀers many opportunities for advancement
of knowledge in particular situations, the very diversity of
these models has made it exceptionally diﬃcult to derive
a comprehensive understanding of the host/pathogen inter-
action. Many of the issues have been discussed previously,
by the present authors [11], and others [12]. Given the
central role of the IL-12 family in the linkage between innate
and adaptive immunity, the purpose of this paper is to
identify commonalities and discrepancies between models of
various manifestations of infection and perhaps thus identify
crucial issues, the resolution of which would facilitate
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their integration into an overall concept of the disease
process.
3.1. Systemic Candidiasis. The importance of innate immu-
nity was first demonstrated by the observation that a
deficiency in the fifth component of complement markedly
increased susceptibility to lethal infection with C. albicans
in mice [13], although this did not aﬀect the development
of specific immune responses in mice that survived [14].
However, neither the severity nor the duration of kidney
infection in C5-deficient mice was influenced by depletion
of T cells [15].
Indeed, T-cell-deficient “nude” [16] and SCID [17] mice
were shown to be no more susceptible than controls to
systemic challenge, and this was confirmed by studies in
mice lacking the α/β chains of the T-cell receptor [18]. These
results demonstrated that innate immune responses were
eﬀective in clearance of the infection, even in the absence
of T-cell-derived cytokines. Furthermore, gene profiling
studies of human monocytes [19] have found a marked
enhancement of proinflammatory cytokines during the first
6 hours after ex vivo exposure to C. albicans, supporting a
dominant role for innate immunity in the early response
against the yeast.
In contrast, there is now a substantial body of literature
on the role of T cells in the development of protective
immune responses following systemic challenge. The ear-
liest of these studies used various combinations of yeasts
(attenuated and virulent), and mouse strains (BALB/c and
DBA/2), to produce healing infections that resolved with
the development of resistance to reinfection, or nonhealing
infections that led to chronic disease and death [12].
Healing combinations showed the development of a Th1
cytokine profile by CD4+ spleen cells in vitro, whereas a
Th2 profile was demonstrated in lymphocytes from animals
with chronic disease. In this context, it is worth noting that
binding of C5a to its receptor on antigen-presenting cells
upregulates IL-12p70, which in turn contributes to IFN-
γ directed T-cell diﬀerentiation toward a Th1 phenotype
[20]. Consequently, the C5-deficient DBA/2, that typically
displayed susceptibility to rechallenge [21], may have a
propensity to develop Th2-type responses, independent of
the nature of the Candida challenge.
In these models, IL-12 was readily demonstrable in
healing infections, whereas the archetypal Th2 cytokine, IL-
4, was found only in animals with progressive infections
[21]. Neutralization of IFN-γ prevented the development
of protective Th1 responses [22], whereas neutralization
of IL-4 reduced mortality, with the induction of a Th1
cytokine profile followed by the development of protective
immunity [23]. In sublethal infection, neutralization of IL-
12 ablated the development of resistance, but administration
of exogenous IL-12 did not result in therapeutic activity [24].
Suppression of a Th2 phenotype—induced in these studies
by treatment of the mice with antibodies against IL-4 or
IL-10—enabled them to overcome the infection and led to
the development of Th1 cytokine profiles [25]. Modulation
of putative interactions between Th1/Th2 cytokines in the
context of Candida infections has been postulated as having
therapeutic potential [25], although recent studies have
demonstrated increasing complexity in such responses.
The eﬀects of IL-12 in these models are presumably
delivered through induction of IFN-γ as mice in which the
IFN-γ receptor had been deleted failed to mount protective
Th1-mediated acquired immunity in response to a live
vaccine strain of the yeast [26]. The impaired Th1-mediated
resistance correlated with defective IL-12 responsiveness, but
IL-12 production was unimpaired. Although inhibition of
Th2 cytokines IL-4 and IL-10 is associated with a reciprocal
polarization towards Th1 responses, germline loss of IL-4 did
not recapitulate these results. IL-4-deficient mice were more
resistant than wild-type animals early after systemic chal-
lenge [27], but eventually succumbed. A failure to develop
Th1-mediated responses in these mice was associated with
defective IFN-γ and IL-12 production, but they retained
responsiveness to IL-12. Administration of exogenous IL-4 in
the later stages of infection upregulated Th1-type responses
and improved outcomes. These data do not readily reconcile
a role for IL-4 in resolving systemic disease; however, they
do demonstrate the importance of being able to mount
an eﬀective Th1 response, which is primarily mediated via
IL-12/IFN-γ.
Although the above makes an impressive case for the
primary role of T helper cells in generating protective
responses against C. albicans infection, tissue susceptibility
is known to be determined by the genetic background of
the mouse [28], and this is associated with diﬀerent patterns
of immune reactivity in the host [29, 30]. Consequently,
it might be expected that some of the disparities observed
in various experimental systems could be attributed to
the background on which the mice were bred (Table 1).
Lavigne and colleagues [31] examined the eﬀects of IL-12
and IFN-γ in the response of C57BL/6 mice to systemic
infection. IL-12 treatment, either alone or in combination,
resulted in the generation of a Th1-like cytokine profile,
with little evidence of IL-4, but paradoxically, treatment
with IL-12 increased the severity of the disease. Antibody-
mediated neutralisation of IFN-γ countered the deleterious
eﬀects of IL-12 administration, suggesting that the induced
lethality was mediated by IFN-γ. This conclusion, however,
was not consistent with results using IFN-γ knockout mice,
which varied depending on the genetic background. If the
knockout was on the BALB/c background, there was no
eﬀect on systemic or gastric candidiasis [32], whereas Balish
[33] found that C57BL/6 × 129 IFN−/− mice were more
susceptible to gastric, anorectal, and acute systemic can-
didiasis than were immunocompetent controls IFN−/− mice
bred on the C57BL/6 background also showed increased
mortality following systemic challenge [34], but this did
not reflect an increased fungal burden in the tissues. IL-
18 and IL-12 are strong stimulators of IFN-γ production,
and in a separate study [35], IL-18−/−, but not IL-12−/−,
mice bred on the C57BL/6 background displayed a similar
increased mortality following systemic challenge with C.
albicans. This was attributed to a marked reduction in
production of IFN-γ and a concomitant decrease in MIP-
2 (macrophage inflammatory protein-2) in the IL-18−/−
mice, and in KC (keratinocyte chemoattractant) in both,
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Table 1: Summary of eﬀects of deletion of selected cytokine genes on susceptibility to systemic and mucosal candidiasis in mice.
Gene deleted Background Oral/Gastrointestinal response Systemic response Reference
IFN-γ BALB/c No eﬀect No eﬀect [32]
IFN-γ C57BL/6 × 129 Susceptible Susceptible [33]
IFN-γ C57BL/6 ND∗ Susceptible [34]
IL-4 BALB/c ND No eﬀect (early) [27]
IL-4 BALB/c No eﬀect No eﬀect [36]
IL-18 C57BL/6 ND Susceptible [35]
IL-12 (p40) BALB/c Susceptible No eﬀect [37]
IL-12 (p40) C57BL/6 ND No eﬀect [35]
IL-12 (p40) C57BL/6 Susceptible No eﬀect [11]
IL-12 (p35) C57BL/6 No eﬀect ND [38]
IL-23 (p19) C57BL/6 Susceptible ND [38]
∗ND, not done.
resulting in a reduced influx of monocytes at the site of
infection.
Mortality following C. albicans infection in outbred
Crl:CF-1 mice was associated with induction of IL-10 [39].
IL-12 and IFN-γ were not detected, and production of
tumour necrosis factor-alpha (TNF-α) was delayed. A strong
eﬀect of the genetic background of the mouse was also
observed after administration of CpG oligodeoxynucleotide,
which has been shown to induce IL-12. The eﬀect was
deleterious in BALB/c [40], whereas in C57BL/6, it conferred
protection that correlated with the early expression of IL-
12 mRNA in the kidneys [41], and an increase in the levels
of IL-12 in the serum. The protective response could not
be induced in (B6; 129SF2/J) TNF-α knockout mice [41],
indicating that IL-12 was induced via a TNF-α-dependent
pathway. The relationship, however, is not straightforward,
as TNF/lymphotoxin (LT)-α double-knockout mice on
the same background were found to be more suscep-
tible to infection, in spite of the production of IL-12
[42].
Some of these apparent conflicts may be attributable
to the morphological plasticity of the growth forms of the
organism and the relative mass of yeasts versus hyphae dur-
ing the initial phases of the host response. In vitro, ingestion
of yeasts activated dendritic cells for IL-12 production and
priming of Th1 cells, whereas ingestion of hyphae inhibited
IL-12 and Th1 priming and induced IL-4 production [43].
Human monocytes cultured with granulocyte-macrophage
colony-stimulating factor and IL-4 after phagocytosis of
Candida yeasts did not diﬀerentiate into dendritic cells yet
secreted high levels of TNF-α and IL-10, but not IL-12
[44]. Monocytes that had phagocytosed germinating forms
diﬀerentiated into mature dendritic cells but were unable
to produce IL-12. These cells were able to prime naive T
cells but not to induce their functional polarization into
eﬀector cells. However, early stages of the dendritic cell
response tended to be dominated by the secretion of pro-
inflammatory and inflammatory mediators, such as IL-8
and TNF-α, although blastoconidia induced markedly lower
cytokine levels than filamentous forms [45].
Inflammatory responses are a dominant feature of the
early response to C. albicans, but these must be under precise
control in order to avoid excessive tissue damage. Dendritic
cells also produce IL-23, which has been shown to regulate
the production of IL-12 [46], thus providing a balance
between host resistance and uncontrolled inflammation. Of
interest is the role of IL-17A in mediating resistance to
systemic infection [47], particularly as exposure of dendritic
cells to hyphae rather than yeast forms has recently been
shown to shift the host toward a Th17 rather than Th1 style
of response [48].
The balance between IL-12 and IL-23 may be determined
by the interactions between the various pattern recognition
receptors and antigenic determinants of the yeast. Interaction
through Dectin-1 induced the maturation of dendritic cells
and the secretion of proinflammatory cytokines, including
IL-6, TNF-α, and IL-23, but little IL-12 [49], whereas Dectin-
2 was activated predominantly by the yeast form [50].
Activation through both Dectin-1 and Dectin-2 promoted
the diﬀerentiation of Th17 cells, which appear to be essential
for host resistance as IL-17A-deficient mice were highly
susceptible to systemic infection [47, 50].
Although the experiments outlined above suggested that
IL-12 played a central role in the development of protective
immune responses against systemic candidiasis, IL-12p40
KOmice were found to be strikingly susceptible to oral infec-
tion, which persisted undiminished for several months [11],
whereas recovery from systemic challenge was unaﬀected.
Interestingly, Conti et al. [38] found that IL-12p35−/− mice,
which had impaired Th1 responses, demonstrated only low
levels of oropharyngeal colonization and no overt disease. In
contrast, Th17-deficient (IL-23p19−/−) and IL-17R-deficient
(IL-17RA−/−) mice developed severe infections. Asmice defi-
cient in the Th17 cytokine IL-22 were onlymildly susceptible,
they concluded that the Th17 lineage, acting largely through
IL-17, mediates the response to oral candidiasis via the
actions of neutrophils and antimicrobial factors.
The issue is further complicated by the demonstration
that germinating C. albicans fails to induce IL-12 p70 [51],
an eﬀect mediated by a soluble product of the germinating
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cells that acted by induction of phosphorylation of ERK44/42
MAPK [52]. Clearly, there are many levels of interaction
between yeasts and host cells that can influence the evolution
of both innate and adaptive immune responses.
3.2. Mucocutaneous Candidiasis. In contrast to their resis-
tance to systemic infection, T-cell-deficient (nude) mice are
acutely susceptible to oral infection [53]. Furthermore, mice
in which the T-cell receptor δ- and α-chains had been
genetically deleted were also highly susceptible to orogastric
candidiasis [18] but remained resistant to acute systemic
candidiasis. These observations strongly suggest that the
predominant host response is diﬀerent in the two types of
infection.
3.2.1. Gastrointestinal Candidiasis. Both normal and T-
cell-deficient mice develop orogastric candidiasis [54], but
only T-cell-suﬃcient mice demonstrate Candida-specific
lymphoproliferation and DTH responses that correlate with
the clearance of C. albicans hyphae from mucosal surfaces.
Depletion of CD4+ lymphocytes increased their suscepti-
bility to Candida infection of the tongue and esophagus
[55], but treatment with anti-IL-2 anti-IFN-γ, or both
did not abrogate their resistance. B-cell knockout mice,
which lack both functional B cells and antibodies, were
as resistant to orogastric candidiasis as immunocompetent
controls [56] a result consistent with a primary role for
cell-mediated immunity in host protection against muco-
cutaneous candidiasis. The γ/δ T cells of the mucosa
have also been implicated in the process of host defence
[57].
Although Th1 responses are important for recovery
from disseminated candidiasis, responses in gastrointestinal
infection were also related to the virulence of the yeast
used for challenge and the “healer” or “nonhealer” status of
the mice. BALB/c mice were resistant to systemic challenge
with the avirulent yeast and generated a protective Th1
cytokine response [58]. In contrast, systemic infection with
the virulent isolate caused early mortality, whereas gastroin-
testinal colonisation with the same yeast resulted in the
production of both Th1- and Th2-type cytokines by CD4+
cells from Peyer’s patches and mesenteric lymph nodes, at a
time when the yeasts were being cleared from the intestine
[59]. Although C5-deficient DBA/2Cr mice developed Th2-
type responses and fatal disseminated candidiasis after
intravenous infection with the avirulent strain yeast [58],
intragastric challenge with the virulent strain resulted in
the induction of Th1-type cell-mediated immune responses
and eventual clearance of the infection [60], demonstrating
again the discrepancy in host responses following systemic or
mucosal challenge.
Administration of soluble IL-4 receptor to mice with
gastrointestinal candidiasis accelerated the clearance of the
fungus from the stomach and stimulated Th1-associated
resistance [61]. IL-12-deficient mice were found to be
highly susceptible to primary gastrointestinal infection or
reinfection, and showed elevated production of IL-4, as well
as reduced production of IFN-γ [37]. Treatment of IL-12-
deficient mice with exogenous IL-12 or IL-10 impaired IL-4
production, and increased resistance to infection, through a
negative eﬀect on the CTLA-4/B7-2 costimulatory pathway.
Although mice in which the genes for particular
cytokines had been deleted were expected to reveal relevant
relationships, such studies have not been particularly illumi-
nating. As noted above, the responses of KOmice appeared to
be heavily influenced by the genetic background. Ablation of
IL-10 increased resistance against both gastrointestinal [62]
and systemic [63] candidiasis in mice bred on the C57BL/6
background, but deletion of the gene for IL-4 had no eﬀect
[34].
A previously unrecognized complication in the inter-
pretation of cytokine profiles in these models comes from
the observation that immunocompetent mouse strains may
develop diﬀerent cytokine profiles, even though they show a
comparable susceptibility to infection. Germ-free C57BL/6
and BALB/c mice were equally susceptible to intestinal
colonization with C. albicans and had similar fungal bur-
dens in gastric tissues 4 weeks after oral challenge [64];
however, C57BL/6 mice responded with increased expression
of TNF-α, IL-12, and the chemokines MIP-2 and KC,
whereas a much more specific and attenuated response was
observed in Candida-infected gastric tissues from BALB/c
mice.
3.2.2. Oral Candidiasis. There is now strong evidence that
CD4+ T cells are essential for clearance of primary infection
from the oral cavity of mice, and these results are consistent
with clinical observations. Both BALB/c and DBA/2 mice
showed a comparable recruitment of CD4+ and CD8+ T
lymphocytes into the mucosal tissue [65] as well as a
substantial increase in intraepithelial CD4+ T cells [66] and
an influx of γ/δ T cells [67] that correlated with a substantial
decrease in the number of viable organisms recovered from
the mucosal tissue [65].
However, mouse strain-specific eﬀects were also
observed, as there was significantly higher Candida-specific
T-cell proliferation in BALB/c as compared to DBA/2 mice
[67]. In the resistant BALB/c mice, rapid clearance of C.
albicans from the oral mucosa was associated with an early
increase in levels of IL-4, IL-12, and IFN-γ in cells from the
cervical lymph nodes, whereas in DBA/2 mice, which cleared
the infection more slowly, IL-4 mRNA was detected later,
and the levels secreted were lower [67]. In BALB/c mice,
monoclonal antibody neutralization of IL-4 increased the
fungal burden and delayed clearance of the yeast. Thus, in
contrast to results in systemically infected mice [23], IL-4
appeared to be an important mediator of protection in oral
candidiasis. Unexpectedly, inhibition of IL-4 production in
susceptible DBA/2 mice was accompanied by an increase
in IFN-γ production [68], which tended to argue against
a strict Th1/Th2 dichotomy as the sole determinant of
resistance and susceptibility in oral candidiasis.
The importance of the T-cell response was demonstrated
by the increased levels of oral colonization in nude mice,
that develop a severe infection that does not clear [53].
Established infections in nude mice could be cleared by
the adoptive transfer of syngeneic CD4+ but not CD8+
lymphocytes [53]. Recovery was associated with the presence
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of IFN-γ and IL-12 in the cervical and submaxillary lymph
nodes of the reconstituted mice. IL-12 and IFN-γ were the
major cytokines produced by lymphocytes from the draining
lymph nodes of animals recovering from oral infection [69],
but levels of IL-4 and IL-10 did not show any association
with recovery. Further studies of oral candidiasis in IFN-γ,
IL-4, IL-10, and iNOS KO mice also failed to demonstrate
any alteration in the severity or course of the disease [36].
In TNF-α KO mice, there was an early increase in the
fungal burden in the oral cavity, but the duration of the
infection was not diﬀerent from controls, and TNF-αwas the
only cytokine that was detected specifically in infected oral
mucosa [70].
This group [71] has also conducted gene-profiling studies
of oral mucosa and draining lymph nodes following oral
colonisation in wild-type and IL-12p40 knockout mice
six days after challenge. They found an upregulation of
soluble inflammatory markers and proteins involved in
tissue remodelling, although at this time after infection, it
could be expected that the infection would be beginning
to be cleared and healing would commence. Conti et al.
[38] similarly demonstrated upregulation of genes associated
with inflammation, and specifically Th17 function, in the
oral mucosa at 24 hours after infection. As depletion
of neutrophils, or inactivation of macrophages/monocytes,
increased the severity of infection [69], there appears to
be a clear linkage between the induction of Th17 cells and
the functional activities of neutrophils, and possibly other
phagocytic cells, in clearance of the yeast.
In oropharyngeal candidiasis, the mucosa represents the
target area for infection, as well as the site that phagocytic
and other eﬀector cells must reach in order to combat
the infection. The matrix metalloproteinases (MMP) are
enzymes crucial for physiological homeostasis, as well as
pathological chemotaxis of immune cells to target tissues
[72]. Following exposure to C. albicans, engineered normal
human oral mucosa showed laminin-5 and type IV collagen
gene activation and protein secretion, as well as MMP-2 and
MMP-9 gene activation, although only the latter was associ-
ated with an increase in active MMP-9 [73]. It was suggested
that these eﬀects might enable C. albicans to overcome the
mechanical and biological defenses of the tissue and allow
it to disseminate, although systemic dissemination following
oro-pharyngeal infections in humans is uncommon.
In the present context, it is worth noting that both
pro- and anti-inflammatory cytokines can modulate MMPs
and their tissue inhibitors. IL-18 and IL-12 both separately
and synergistically enhanced MMP-2, while TNF-α led to
the elevation of MMP-9. All proinflammatory cytokines
enhanced MT1-MMP expression, and IL-4 suppressed TNF-
α-induced MMP-9 expression [74]. On the other hand, the
inhibitory eﬀect of IL-12 on MMP9 expression in activated
peripheral bloodmononuclear cells (PBMCs), as well as their
ability to transmigrate across an extracellular matrix, was
enhanced in the presence of endothelial cells, and conversely,
stimulated PBMCs reduced the expression and the activity
of MMP9 [75]. It is, therefore, possible that the presence of
TNF-α in the oral mucosa in the early stages of infection [70]
may, by stimulating production of MMP9, be instrumental
in facilitating the passage of inflammatory cells into the
oral mucosa, whereas later in the course of infection, IL-12
downregulates this activity.
4. Conclusion
A concept that would integrate the disparate responses
to systemic and mucosal candidiasis remains elusive. IL-
12, thought to be at the centre of such responses, has
been reevaluated in the light of the functions of IL-23 and
somewhat overshadowed in importance by the Th17 cells
and their cytokines, whose pivotal role in oral candidiasis
now seems well established. However, although the evidence
indicates that IL-17 does play a role in the response against
systemic infection, the precise role of T cells in this system
is unclear, and inconsistencies and contradictions between
the various models still remain. Although approaches such
as gene profiling identify a plethora of candidate genes
either up- or downregulated in host responses, validation
of the biochemical pathways involved will still be required,
and confirmation in animal models remains the gold
standard.
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